Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Arch Biopartners Inc (V: ARCH)

 
ARCH Technical Analysis
1
As on 10th Feb 2026 ARCH STOCK Price closed @ 0.89 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ARCHSTOCK Price

Open 0.77 Change Price %
High 0.89 1 Day N/A N/A
Low 0.70 1 Week 0.00 0.00
Close 0.89 1 Month 0.00 0.00
Volume 1370893 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
V Canada Most Active Stocks
SML 1503.80 5.80%
NU 16.76 39.32%
GXU 0.04 0.00%
DAU 0.08 %
AUMB 0.99 %
SNS 0.40 -2.44%
NAU 1.21 %
SLVR 0.99 %
MGG 0.57 %
CDB 1.19 %
 
V Canada Top Gainers Stocks
KUB 7.50 37400.00%
CEN 19.16 27271.43%
CEN 19.16 27271.43%
CEN 19.16 27271.43%
CEN 19.16 27271.43%
CEN 19.16 27271.43%
PRE 1.55 7650.00%
PRE 1.55 7650.00%
HELX 32.31 4096.10%
CROW-P 0.72 500.00%
 
V Canada Top Losers Stocks
VEC 43.92 -99.71%
VEC 43.92 -99.71%
VEC 43.92 -99.71%
VEC 43.92 -99.71%
TZR 0.05 -75.00%
ORC-A 20.00 -67.21%
SGMA 4.18 -63.65%
SGMA 4.18 -63.65%
ATI 0.03 -62.50%
ATI 0.03 -62.50%
 
 
ARCH
Daily Charts		 ARCH
Intraday Charts		 Whats New @
Bazaartrend		 ARCH
Free Analysis
 
ARCH Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
ARCH Forecast February 2026
Share
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
ARCH Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
ARCH Forecast2026
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
ARCH Other Details
Segment EQ
Market Capital 166678592.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ARCH Address
ARCH
 
ARCH Latest News
 
Your Comments and Response on Arch Biopartners Inc
 
ARCH Business Profile
Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. It focuses on developing its lead drug candidate MetaBlok, which is in Phase II for the treatment or prevention of dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver, or kidneys. The company also develops AB569, a drug candidate for the treatment of antibiotic resistant bacterial infections, primarily in the lungs and wounds, as well as to treat pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. In addition, the company develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is headquartered in Toronto, Canada. Address: 27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service